Takeda would be one of many. By value of other drugs we can make some conclusions. This one is in early development but they still paid 4 billion cash plus they add 2 billion on sale mile stones. Big deals do happen.
Now looking at Remestemcel, we have mode of action for GVHD and we have results. They are already accross other indications including IBD. We have the potancy assay. Given FDA approval our product is worth something well north of above.
Is 4 billion cash plus 20 % of sales over the top?
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-185
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.0¢ | $2.617M | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 107932 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 34142 | 1 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |